The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Epigenetics provides a new generation of oncogenes and tumour-suppressor genes
Open accessAbstract
Cancer is nowadays recognised as a genetic and epigenetic disease. Much effort has been devoted in the last 30 years to the elucidation of the 'classical' oncogenes and tumour-suppressor genes involved in malignant cell transformation. However, since the acceptance that major disruption of DNA methylation, histone modification and chromatin compartments are a common hallmark of human cancer, epigenetics has come to the fore in cancer research. One piece is still missing from the story: are the epigenetic genes themselves driving forces on the road to tumorigenesis? We are in the early stages of finding the answer, and the data are beginning to appear: knockout mice defective in DNA methyltransferases, methyl-CpG-binding proteins and histone methyltransferases strongly affect the risk of cancer onset; somatic mutations, homozygous deletions and methylation-associated silencing of histone acetyltransferases, histone methyltransferases and chromatin remodelling factors are being found in human tumours; and the first cancer-prone families arising from germline mutations in epigenetic genes, such as hSNF5/INI1, have been described. Even more importantly, all these 'new' oncogenes and tumour-suppressor genes provide novel molecular targets for designed therapies, and the first DNA-demethylating agents and inhibitors of histone deacetylases are reaching the bedside of patients with haematological malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg542 · Cited by 1,196
Zebularine: a new drug for epigenetic therapy
Yoo, C. B., Cheng, J. C., & Jones, P. A. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320910 · Cited by 191
Cited by
Environmental epigenomics and disease susceptibility
Jirtle, R. L., & Skinner, M. K. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2045 · Cited by 2,492
The natural history of cervical HPV infection: unresolved issues
Woodman, C. B. J., Collins, S. I., & Young, L. S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2050 · Cited by 1,033
Global Levels of Histone Modifications Predict Prognosis in Different Cancers
Seligson, D. B., Horvath, S., McBrian, M. A., Mah, V., Yu, H., Tze, S., Wang, Q., Chia, D., Goodglick, L., & Kurdistani, S. K. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080874 · Cited by 508
Comprehensive high-throughput arrays for relative methylation (CHARM)
Irizarry, R. A., Ladd-Acosta, C., Carvalho, B., Wu, H., Brandenburg, S. A., Jeddeloh, J. A., Wen, B., & Feinberg, A. P. (2008) · Genome Research · doi:10.1101/gr.7301508 · Cited by 433
Cell Plasticity and Heterogeneity in Cancer
Marjanovic, N. D., Weinberg, R. A., & Chaffer, C. L. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.184655 · Cited by 400
Metadata
- Authors
- Esteller, M.
- Venue
- British Journal of Cancer
- Published
- 2006-01
- Volume
- 94
- Issue
- 2
- Pages
- 179-183
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2126427849
- Cited by
- 284
- References
- 2
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. https://app.cochat.ai/papers/10.1038/sj.bjc.6602918
- The paper
- Esteller, M. (2006). Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6602918
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.